OpenLB
Open Library of Bioscience
Advanced Search

Journal

Publication Year

1 year 3 years 5 years 10 years
2021 - 2032
202120222023
202420252026
202720282029
203020312032
2021 - 2032
202120222023
202420252026
202720282029
203020312032

Publication Type

Associated Data

Found 151 results

Filters: VX-809 (lumacaftor)

Corrector VX-809 promotes interactions between cytoplasmic loop one and the first nucleotide-binding domain of CFTR.
Tip W Loo, David M Clarke
Biochem Pharmacol. 07 15, 2017.136:24-31 Print-Electronic
Source:PubMed
PMID: 28366727 doi:10.1016/j.bcp.2017.03.020
Distinct proteostasis states drive pharmacologic chaperone susceptibility for Cystic Fibrosis Transmembrane Conductance Regulator misfolding mutants
McDonald, E. F.; Sabusap, C. M. P.; Kim, M.; Plate, L.
biorxiv. 2021-09-09. Preprint
Source:biorxiv
PPRID: 10.1101/2021.09.09.459524v1 doi:NA
Lumacaftor (VX-809) restores the ability of CF macrophages to phagocytose and kill Pseudomonas aeruginosa.
Roxanna Barnaby, Katja Koeppen, Amanda Nymon, Thomas H Hampton, Brent Berwin, Alix Ashare, Bruce A Stanton
Am J Physiol Lung Cell Mol Physiol. 03 01, 2018.314(3):L432-L438 Print-Electronic
Source:PubMed
PMID: 29146575 doi:10.1152/ajplung.00461.2017
The investigational Cystic Fibrosis drug Trimethylangelicin directly modulates CFTR by stabilizing the first membrane-spanning domain.
Onofrio Laselva, Steven Molinski, Valeria Casavola, Christine E Bear
Biochem Pharmacol. Nov 01, 2016.119:85-92 Print-Electronic
Source:PubMed
PMID: 27614011 doi:10.1016/j.bcp.2016.09.005
Lumacaftor alone and combined with ivacaftor: preclinical and clinical trial experience of F508del CFTR correction.
John J Brewington, Gary L McPhail, John P Clancy
Expert Rev Respir Med. 2016.10(1):5-17 Print-Electronic
Source:PubMed
PMID: 26581802 doi:10.1586/17476348.2016.1122527
Low free drug concentration prevents inhibition of F508del CFTR functional expression by the potentiator VX-770 (ivacaftor).
Elizabeth Matthes, Julie Goepp, Graeme W Carlile, Yishan Luo, Kurt Dejgaard, Arnaud Billet, Renaud Robert, David Y Thomas, John W Hanrahan
Br J Pharmacol. Feb, 2016.173(3):459-70 Print-Electronic
Source:PubMed
PMID: 26492939 doi:10.1111/bph.13365
Direct interaction of a CFTR potentiator and a CFTR corrector with phospholipid bilayers.
Debora Baroni, Olga Zegarra-Moran, Agneta Svensson, Oscar Moran
Eur Biophys J. Jul, 2014.43(6-7):341-6 Print-Electronic
Source:PubMed
PMID: 24771136 doi:10.1007/s00249-014-0956-y
Combined effects of VX-770 and VX-809 on several functional abnormalities of F508del-CFTR channels.
Z Kopeikin, Z Yuksek, H-Y Yang, S G Bompadre
J Cyst Fibros. Sep, 2014.13(5):508-14 Print-Electronic
Source:PubMed
PMID: 24796242 doi:10.1016/j.jcf.2014.04.003
Elexacaftor/VX-445-mediated CFTR interactome remodeling reveals differential correction driven by mutation-specific translational dynamics
Kim, M.; McDonald, E. F.; Sabusap, C. M. P.; Timalsina, B.; Joshi, D.; Hong, J. S.; Rab, A.; Sorscher, E. J.; Plate, L.
biorxiv. 2023-02-04. Preprint
Source:biorxiv
PPRID: 10.1101/2023.02.04.527134v1 doi:NA
Corrector VX-809 stabilizes the first transmembrane domain of CFTR.
Tip W Loo, M Claire Bartlett, David M Clarke
Biochem Pharmacol. Sep 01, 2013.86(5):612-9 Print-Electronic
Source:PubMed
PMID: 23835419 doi:10.1016/j.bcp.2013.06.028
0